Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesAura Biosciences Inc

Aura Biosciences Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
7.61 USD 0.00(0%)
Last update at 2026-11-11T21:00:00Z
VOLUME
648447
Market Cap
452.26M

Momentum Score

…

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. It focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer. The company was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
7.31
Low
7.71
High
52 Week Price Range
4.34
Low
7.48
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Aura Biosciences is a clinical-stage biotechnology company developing tumor-targeted, near-infrared–activated cytolytic agents built on a proprietary virus-like particle platform, with its lead program focused on uveal (ocular) melanoma. Major long-term growth drivers include clinical trial progress toward regulatory approvals, platform extension into additional oncology indications, and strategic collaborations to commercialize novel therapies; investors may find the company attractive because its differentiated activation mechanism may provide targeted tumor cell killing with reduced systemic exposure if clinical data are positive.
The principal investment risks are clinical and regulatory failure combined with substantial cash burn and the likely need for additional financing to continue development.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
7.61
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.13
ROE
-73.52%
Net Debt
-42.14M
ROCE
-74.67%
Diluted EPS TTM
-1.76

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -106.08M -86.81M -76.27M -58.76M -35.25M
Net income -106.19M -86.92M -76.41M -57.23M -34.42M
Selling general administrative 22.49M 22.81M 19.76M 18.06M 10.09M
Selling and marketing expenses - - 19.74M - -
Gross profit - -1.22M -1.29M -60.30M -35.25M
Reconciled depreciation 1.13M 1.22M 1.29M 1.18M 0.83M
Ebit -112.79M -96.12M -84.99M -60.30M -35.25M
Ebitda -111.66M -94.89M -83.70M -59.97M -35.24M
Depreciation and amortization 1.13M 1.22M 1.29M 0.33M 0.01M
Non operating income net other - - - 1.53M -0.00M
Operating income -112.79M -96.12M -84.99M -60.30M -35.25M
Other operating expenses 112.79M 96.12M 84.99M 60.30M 35.25M
Interest expense - - - 0.85M 0.01M
Tax provision 0.11M 0.11M 0.14M - -
Interest income 6.63M 9.43M 7.04M 1.86M -
Net interest income 6.63M 9.43M 7.04M 1.86M 0.01M
Income tax expense 0.11M 0.11M 0.14M -1.53M -0.83M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 112.79M 96.12M 83.70M 60.30M 35.25M
Cost of revenue - 1.22M 1.29M 60.30M 35.25M
Total other income expense net 6.71M 9.31M 8.72M 1.53M -0.00M
Net income from continuing ops -106.19M -86.92M -70.84M -58.76M -35.25M
Net income applicable to common shares - - - -58.76M -35.25M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 169.43M 182.50M 255.07M 223.94M 160.03M
Other current assets 5.50M 9.53M 5.62M 7.87M 4.62M
Total liab 32.52M 30.53M 29.23M 28.35M 7.71M
Total stockholder equity 136.91M 151.97M 225.85M 195.58M 152.31M
Other current liab 13.59M 9.46M 7.88M 4.57M 0.42M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -480.42M -374.23M -287.31M -210.90M -152.14M
Other liab - - - - 0.08M
Other assets - - 0.00M 1.19M 0.12M
Cash 59.52M 31.69M 41.08M 121.58M 149.06M
Total current liabilities 18.38M 14.91M 12.36M 10.46M 7.27M
Current deferred revenue - - - - 3.83M
Net debt -42.14M -12.92M -21.52M -100.72M -148.09M
Short term debt 3.24M 3.15M 2.69M 2.96M 0.61M
Short long term debt total 17.38M 18.77M 19.56M 20.86M 0.97M
Other stockholder equity 617.43M 525.93M 512.62M 406.56M 144.42M
Property plant equipment - - - 5.37M 5.25M
Total current assets 149.74M 160.62M 231.79M 196.70M 153.70M
Net tangible assets - - - 195.58M 152.31M
Short term investments 84.73M 119.40M 185.09M 67.23M -
Accounts payable 1.55M 2.30M 1.79M 2.92M 2.40M
Accumulated other comprehensive income -0.10M 0.26M 0.54M -0.07M -
Retained earnings total equity - - - -210.90M -152.14M
Non currrent assets other 1.24M 1.29M 0.51M 1.19M 0.12M
Non current assets total 19.69M 21.88M 23.28M 27.23M 6.33M
Capital lease obligations 17.38M 18.77M 19.56M 20.86M 0.97M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 36.04M 68.82M -40.72M -66.78M -2.12M
Change to liabilities - - - 0.57M 3.26M
Total cashflows from investing activities 35.59M 68.82M -113.96M -67.87M -2.12M
Total cash from financing activities 77.16M 1.59M 97.29M 95.63M 166.26M
Change to operating activities - - - -3.44M -1.37M
Net income -106.19M -86.92M -76.41M -58.76M -35.25M
Change in cash 27.82M -9.39M -80.52M -26.84M 131.72M
Begin period cash flow 32.46M 41.85M 122.37M 149.21M 17.49M
End period cash flow 60.28M 32.46M 41.85M 122.37M 149.21M
Total cash from operating activities -84.74M -79.81M -63.85M -54.60M -32.41M
Issuance of capital stock 52.57M 0.00M 98.37M 95.20M 165.93M
Depreciation 1.13M 1.22M 1.29M 1.18M 0.83M
Other cashflows from investing activities - -0.00M - - -
Sale purchase of stock - - - 87.08M 166.27M
Other cashflows from financing activities 77.16M 1.59M 94.12M 87.08M 87.56M
Change to netincome - - - 6.09M 2.32M
Capital expenditures 0.45M 1.25M 0.71M 1.09M 2.12M
Cash flows other operating - - - -3.68M -3.57M
Cash and cash equivalents changes - - - -26.84M 131.72M
Change in working capital 5.97M -2.64M 4.44M -3.10M -0.32M
Stock based compensation 14.32M 11.72M 8.77M 6.41M 2.31M
Other non cash items 0.03M -3.19M -1.95M -0.33M 0.00M
Free cash flow -85.19M -81.06M -64.56M -55.70M -34.53M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
AURA
Aura Biosciences Inc		 -
-%		 7.61 - - - 3.31 -5.68
NVO
Novo Nordisk A/S		 0.41
1.00%		 41.10 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.86
0.16%		 547.03 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 43.35
4.73%		 959.41 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Aura Biosciences Inc

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. It focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer. The company was incorporated in 2009 and is headquartered in Boston, Massachusetts.

80 Guest Street, Boston, MA, United States, 02135

617 500 8864

https://www.aurabiosciences.com

113

Name Title Year Born
Dr. Elisabet de los Pinos Ph.D. Founder, CEO, Pres & Director 1974
Ms. Julie B. Feder CFO, Sec. & Treasurer 1970
Dr. Cadmus Collins Rich CPE, M.B.A., M.D., MBA Chief Medical Officer and Head of R&D 1965
Dr. Mark A. De Rosch Ph.D. Chief Operating Officer 1964
Mr. Paulo Carvalho VP of Technical Operations NA
Mr. Joseph Lyons VP of HR NA
Ms. Michele Keough M.B.A. Sr. VP of Project Management and Device Supply Chain NA
Dr. Elisabet de los Pinos Ph.D. Founder, CEO, President & Director 1973
Ms. Julie B. Feder CFO, Secretary & Treasurer 1970
Dr. Mark Plavsic D.V.M., Ph.D. Chief Technology Officer 1962

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

MAL
CAD 38.85
+13.53%
SOIL
CAD 8.39
+12.02%
QNC
CAD 1.48
+10.45%
TCL-B
CAD 7.26
+9.01%
CLS
CAD 345.53
+8.41%
GSY
CAD 37.75
-16.04%
BYD
CAD 109.98
-11.99%
ELE
CAD 20.12
-11.95%
LAC
CAD 2.39
-11.15%
CFW
CAD 6.51
-10.82%

Equity Sectors*

  • Basic Materials

    -1.75%

  • Communication Services

    +0.20%

  • Consumer Cyclical

    +0.18%

  • Consumer Defensive

    +0.06%

  • Energy

    +1.65%

  • Financial Services

    +0.10%

  • Healthcare

    +1.25%

  • Industrials

    +1.60%

  • Real Estate

    -0.29%

  • Technology

    +2.72%

  • Utilities

    +0.12%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…